Bispecific antibodies targeting mutant RAS neoantigens-Reference-Cited by-同舟云学术

Bispecific antibodies targeting mutant RAS neoantigens

Published:2021-03-04 Issue:57 Volume:6 Page:
ISSN:2470-9468
Container-title:Science Immunology
language:en
Short-container-title:Sci. Immunol.

Author:

Douglass Jacqueline¹²³^ORCID,Hsiue Emily Han-Chung¹²³^ORCID,Mog Brian J.¹²³⁴^ORCID,Hwang Michael S.¹²³,DiNapoli Sarah R.¹²³^ORCID,Pearlman Alexander H.¹²³^ORCID,Miller Michelle S.²⁵⁶^ORCID,Wright Katharine M.²⁵⁶^ORCID,Azurmendi P. Aitana²⁵⁶^ORCID,Wang Qing¹²⁷^ORCID,Paul Suman¹²³⁸^ORCID,Schaefer Annika¹²³^ORCID,Skora Andrew D.¹²^ORCID,Molin Marco Dal¹⁹^ORCID,Konig Maximilian F.¹²³¹⁰^ORCID,Liu Qiang¹²³^ORCID,Watson Evangeline¹²³,Li Yana⁵^ORCID,Murphy Michael B.¹¹^ORCID,Pardoll Drew M.⁶⁸^ORCID,Bettegowda Chetan¹³¹²^ORCID,Papadopoulos Nickolas¹³⁶¹³^ORCID,Gabelli Sandra B.⁵⁸¹⁴^ORCID,Kinzler Kenneth W.¹³⁶^ORCID,Vogelstein Bert¹²³⁶¹³^ORCID,Zhou Shibin¹³⁶^ORCID

Affiliation:

1. Ludwig Center, Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University School of Medicine, Baltimore, MD 21287, USA.

2. Howard Hughes Medical Institute, Chevy Chase, MD 20815, USA.

3. Lustgarten Pancreatic Cancer Research Laboratory, Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University School of Medicine, Baltimore, MD 21287, USA.

4. Department of Biomedical Engineering, Johns Hopkins University, Baltimore, MD 21218, USA.

5. Department of Biophysics and Biophysical Chemistry, Johns Hopkins University School of Medicine, Baltimore, MD 21287, USA.

6. Bloomberg~Kimmel Institute for Cancer Immunotherapy, Sidney Kimmel Comprehensive Cancer Center, Baltimore, MD 21287, USA.

7. Complete Omics Inc., Baltimore, MD 21227, USA.

8. Department of Oncology, Johns Hopkins University School of Medicine, Baltimore, MD 21287, USA.

9. Department of Surgery, University of Maryland Medical Center, Baltimore, MD 21201, USA.

10. Division of Rheumatology, Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, MD 21224, USA.

11. Cytiva, Marlborough, MA 01752, USA.

12. Department of Neurosurgery, Johns Hopkins University School of Medicine, MD 21205, USA.

13. Department of Pathology, Johns Hopkins University School of Medicine, Baltimore, MD 21205, USA.

14. Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, MD 21205, USA.

Abstract

Bispecific T cell–engaging antibodies capable of specifically killing cancer cells expressing mutant RAS neoantigens were generated.

Funder

NIH Office of the Director

National Cancer Institute

Commonwealth Fund

Lustgarten Foundation

Bloomberg~Kimmel Institute for Cancer Immunotherapy, Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University

Bloomberg Philanthropies

The Virginia and D.K. Ludwig Fund for Cancer Research

The Mark Foundation for Cancer Research

NIH Cancer Center Support

National Institute of Arthritis and Musculoskeletal and Skin Diseases of the National Institutes of Health

SITC-Amgen Cancer Immunotherapy in Hematologic Malignancies Fellowship

Publisher

American Association for the Advancement of Science (AAAS)

Subject

General Medicine,Immunology

Reference71 articles.

1. Cancer Genome Landscapes

2. Small molecules, big impact: 20 years of targeted therapy in oncology

3. Identification of T-cell Receptors Targeting KRAS-Mutated Human Tumors

4. The clinical KRAS(G12C) inhibitor AMG 510 drives anti-tumour immunity

5. T-Cell Transfer Therapy Targeting Mutant KRAS in Cancer

Cited by 119 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Potent antitumor activity of a bispecific T-cell engager antibody targeting the intracellular antigen KRAS G12V;Biomolecules and Biomedicine;2024-09-06

2. T cell-redirecting therapies in hematological malignancies: Current developments and novel strategies for improved targeting;Molecular Therapy;2024-09

3. TCR-like bispecific antibodies toward eliminating infected hepatocytes in HBV mouse models;Emerging Microbes & Infections;2024-08-08

4. Nomogram for predicting survival after first-line anti-PD-1-based immunotherapy in unresectable stage IV melanoma: a multicenter international study;ESMO Open;2024-08

5. Unlocking the potential of bispecific ADCs for targeted cancer therapy;Frontiers of Medicine;2024-07-23